GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (NAS:DXR) » Definitions » EV-to-FCF

Daxor (DXR) EV-to-FCF : -12.98 (As of May. 03, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Daxor EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Daxor's Enterprise Value is $47.43 Mil. Daxor's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.66 Mil. Therefore, Daxor's EV-to-FCF for today is -12.98.

The historical rank and industry rank for Daxor's EV-to-FCF or its related term are showing as below:

DXR' s EV-to-FCF Range Over the Past 10 Years
Min: -185.11   Med: -16.51   Max: 29.06
Current: -13.2

During the past 13 years, the highest EV-to-FCF of Daxor was 29.06. The lowest was -185.11. And the median was -16.51.

DXR's EV-to-FCF is ranked worse than
100% of 365 companies
in the Medical Devices & Instruments industry
Industry Median: 28.26 vs DXR: -13.20

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-03), Daxor's stock price is $9.71. Daxor's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.720. Therefore, Daxor's PE Ratio for today is At Loss.


Daxor EV-to-FCF Historical Data

The historical data trend for Daxor's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daxor EV-to-FCF Chart

Daxor Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.75 -20.67 -17.62 -52.71 -12.83

Daxor Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.62 - -52.71 - -12.83

Competitive Comparison of Daxor's EV-to-FCF

For the Medical Instruments & Supplies subindustry, Daxor's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daxor's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Daxor's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Daxor's EV-to-FCF falls into.



Daxor EV-to-FCF Calculation

Daxor's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=47.426/-3.655
=-12.98

Daxor's current Enterprise Value is $47.43 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Daxor's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daxor  (NAS:DXR) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Daxor's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9.71/-0.720
=At Loss

Daxor's share price for today is $9.71.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Daxor's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.720.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Daxor EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Daxor's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Daxor (DXR) Business Description

Traded in Other Exchanges
Address
109 Meco Lane, Oak Ridge, TN, USA, 37830
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Executives
Robert J Michel officer: CHIEF FINANCIAL OFFICER C/O ASTA FUNDING, INC., 210 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Michael Richard Feldschuh director 71 GRAND STREET #2, NEW YORK NY 10013
Joy S. Goudie director 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Caleb Desrosiers director DAXOR CORPORATION, 109 MECO LANE, OAK RIDGE TN 37830
Henry D. Cremisi director 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Edward Feuer director 2 WALL STREET, 10TH FLOOR, NEW YORK NY 10005
Soren Thompson officer: V.P./BUSINESS DEVELOPMENT 180 CENTRAL PARK SOUTH, APT. 805, NEW YORK NY 10019
Jonathan Adam Feldschuh director, officer: CHIEF SCIENTIFIC OFFICER DAXOR CORPORATION, 350 5TH AVENUE, SUITE 4740, NEW YORK NY 10118
Joseph Feldschuh officer: President 615 W. 252ND STREET, BRONX NY 10471
Estate Of Joseph Feldschuh other: FOUNDER 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Diane Marie Meegan officer: Corporate Secretary 259 NEW YORK AVENUE, JERSEY CITY NJ 07307
Bernhard Saxe director 6805 WILD ROSE COURT, SPRINGFIELD VA 25152
Robert Willens director 200 EAST 74TH ST APT 18C, NEW YORK NY 10021
Philip Nordan Hudson director P.O. BOX 160892, SAN ANTONIO TX 78280-3092
Everis Engstrom officer: Vice President 3244 BLACK FOX ROAD, WASHBURN TN 37888

Daxor (DXR) Headlines

From GuruFocus

Daxor Corporation Announces Proposed Underwritten Public Offering

By GlobeNewswire GlobeNewswire 05-19-2023